LLY vs PRLD · P/E 39, rev $22.97B vs rev $10.3M
Eli Lilly and Company (LLY) versus Prelude Therapeutics Inc (PRLD) — a side-by-side from cached financials, not a winner call.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Prelude Therapeutics Inc (PRLD) is a biotechnology company listed on NASDAQ.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Latest reported PRLD revenue for 2026-06-30 was $10.3M. Net income was -$24.3M. PRLD currently screens at market cap $346.5M.
LLY currently screens at market cap $991.62B and trailing P/E 39.5. PRLD currently screens at market cap $346.5M.
Not investment advice. Open the LLY and PRLD stock pages for the full models.
Not investment advice.